Advertisement

BioRelix Inc., a biotech based in New Haven, Conn., has taken in $2.4 million of a planned $4.8 million debt and warrants financing, according to a filing with the U.S. Securities and Exchange Commission.

The company develops infectious disease treatments using RNA targets called RiboSwitches, which are found in bacteria and fungi, the BioRelix website explains. It was founded upon scientific research by Ronald Breaker, who discovered RiboSwitches in his lab at Yale University.

SOURCE

Advertisement
Advertisement